|
2025-03-27 |
2025-03-25 |
PP
Planned purchase
|
Combs Andrew
Chief Chemistry Officer
Officer
|
100,000
+26.3%
0.69
USD 69,250
|
100,000
+26.3%
|
0.69
|
USD 69,250
|
|
|
2025-03-27 |
2025-03-25 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
675,000
+51.0%
0.69
USD 467,438
|
675,000
+51.0%
|
0.69
|
USD 467,438
|
|
|
2025-03-24 |
2025-03-21 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
15,000
+1.1%
0.73
USD 10,959
|
15,000
+1.1%
|
0.73
|
USD 10,959
|
|
|
2025-03-24 |
2025-03-20 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
5,416
+0.4%
0.73
USD 3,950
|
5,416
+0.4%
|
0.73
|
USD 3,950
|
|
|
2025-03-18 |
2025-03-17 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
9,106
+0.7%
0.75
USD 6,829
|
9,106
+0.7%
|
0.75
|
USD 6,829
|
|
|
2025-03-18 |
2025-03-14 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
29,999
+2.4%
0.75
USD 22,631
|
29,999
+2.4%
|
0.75
|
USD 22,631
|
|
|
2025-03-14 |
2025-03-13 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
50,000
+4.1%
0.72
USD 35,820
|
50,000
+4.1%
|
0.72
|
USD 35,820
|
|
|
2025-03-14 |
2025-03-12 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
47,500
+4.1%
0.71
USD 33,744
|
47,500
+4.1%
|
0.71
|
USD 33,744
|
|
|
2025-01-03 |
2024-12-31 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
5,000
+3.6%
1.21
USD 6,044
|
5,000
+3.6%
|
1.21
|
USD 6,044
|
|
|
2025-01-02 |
2024-12-30 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
10,000
+7.8%
1.20
USD 12,000
|
10,000
+7.8%
|
1.20
|
USD 12,000
|
|
|
2024-12-26 |
2024-12-23 |
B
Purchase
|
Combs Andrew
Chief Chemistry Officer
Officer
|
60,000
+18.9%
1.37
USD 82,002
|
60,000
+18.9%
|
1.37
|
USD 82,002
|
|
|
2024-12-26 |
2024-12-20 |
PP
Planned purchase
|
Combs Andrew
Chief Chemistry Officer
Officer
|
3,075
+1.0%
1.15
USD 3,536
|
3,075
+1.0%
|
1.15
|
USD 3,536
|
|
|
2024-12-20 |
2024-12-19 |
B
Purchase
|
Lim Bryant David
CLO, Interim CFO, Corp Sec.
Officer
|
25,000
+1041.7%
0.91
USD 22,638
|
25,000
+1041.7%
|
0.91
|
USD 22,638
|
|
|
2024-12-20 |
2024-12-19 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
6,888
+5.7%
0.89
USD 6,116
|
6,888
+5.7%
|
0.89
|
USD 6,116
|
|
|
2024-12-20 |
2024-12-18 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
100,000
+9.4%
0.93
USD 93,210
|
100,000
+9.4%
|
0.93
|
USD 93,210
|
|
|
2023-05-26 |
2023-05-25 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
900
+0.1%
5.31
USD 4,779
|
900
+0.1%
|
5.31
|
USD 4,779
|
|
|
2023-05-26 |
2023-05-24 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
1,000
+0.1%
5.01
USD 5,011
|
1,000
+0.1%
|
5.01
|
USD 5,011
|
|
|
2023-05-25 |
2023-05-24 |
B
Purchase
|
Lim Bryant David
Chief Legal Officer, Corp Sec.
Officer
|
2,400
+inf%
5.39
USD 12,936
|
2,400
+inf%
|
5.39
|
USD 12,936
|
|
|
2023-05-25 |
2023-05-23 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
11,856
+1.1%
5.63
USD 66,749
|
11,856
+1.1%
|
5.63
|
USD 66,749
|
|
|
2023-05-25 |
2023-05-23 |
PP
Planned purchase
|
Chardonnet Laurent
Chief Financial Officer
Officer
|
5,000
+13.5%
5.50
USD 27,500
|
5,000
+13.5%
|
5.50
|
USD 27,500
|
|
|
2023-05-24 |
2023-05-22 |
B
Purchase
|
ORBIMED ADVISORS LLC
Non-Executive Director
Large shareholder
|
869,565
+9.4%
5.75
USD 4,999,999
|
869,565
+9.4%
|
5.75
|
USD 4,999,999
|
|
|
2023-05-24 |
2023-05-22 |
B
Purchase
|
Bonita David P
Non-Executive Director
Large shareholder
|
869,565
+9.4%
5.75
USD 4,999,999
|
869,565
+9.4%
|
5.75
|
USD 4,999,999
|
|
|
2023-04-06 |
2023-04-06 |
S
Sale
|
Huang Jane
President, CMO
Officer
|
13,280
-35.4%
6.12
USD 81,274
|
13,280
-35.4%
|
6.12
|
USD 81,274
|
|
|
2022-12-21 |
2022-12-20 |
B
Purchase
|
Vaddi Krishna
CEO
Executive Director
|
19,188
+18.9%
5.13
USD 98,446
|
19,188
+18.9%
|
5.13
|
USD 98,446
|
|
|
2022-12-12 |
2022-12-08 |
PP
Planned purchase
|
Chardonnet Laurent
Chief Financial Officer
Officer
|
10,000
+38.7%
4.76
USD 47,600
|
10,000
+38.7%
|
4.76
|
USD 47,600
|
|
|
2022-06-01 |
2022-06-01 |
B
Purchase
|
Chardonnet Laurent
Chief Financial Officer
Officer
|
10,000
+69.0%
4.23
USD 42,300
|
10,000
+69.0%
|
4.23
|
USD 42,300
|
|
|
2021-12-17 |
2021-12-15 |
PS
Planned sale
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Officer
|
28,751
-98.5%
13.00
USD 373,763
|
28,751
-98.5%
|
13.00
|
USD 373,763
|
|
|
2021-12-15 |
2021-12-14 |
B
Purchase
|
Combs Andrew
EVP, Head of Chemistry
Officer
|
4,000
+1.5%
11.60
USD 46,400
|
4,000
+1.5%
|
11.60
|
USD 46,400
|
|
|
2021-12-15 |
2021-12-13 |
B
Purchase
|
Combs Andrew
EVP, Head of Chemistry
Officer
|
4,000
+1.5%
12.12
USD 48,480
|
4,000
+1.5%
|
12.12
|
USD 48,480
|
|
|
2021-11-18 |
2021-11-16 |
PS
Planned sale
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Officer
|
400
-47.4%
16.43
USD 6,570
|
400
-47.4%
|
16.43
|
USD 6,570
|
|
|
2021-11-18 |
2021-11-16 |
PS
Planned sale
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Officer
|
28,351
-97.1%
15.87
USD 449,962
|
28,351
-97.1%
|
15.87
|
USD 449,962
|
|
|
2021-10-06 |
2021-10-05 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
1,289
-100.0%
32.06
USD 41,330
|
1,289
-100.0%
|
32.06
|
USD 41,330
|
|
|
2021-10-06 |
2021-10-05 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
7,803
-85.8%
31.30
USD 244,257
|
7,803
-85.8%
|
31.30
|
USD 244,257
|
|
|
2021-10-06 |
2021-10-05 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
5,908
-39.4%
30.26
USD 178,762
|
5,908
-39.4%
|
30.26
|
USD 178,762
|
|
|
2021-06-09 |
2021-06-07 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
12,700
-100.0%
32.73
USD 415,665
|
12,700
-100.0%
|
32.73
|
USD 415,665
|
|
|
2021-06-09 |
2021-06-07 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
900
-6.6%
31.62
USD 28,462
|
900
-6.6%
|
31.62
|
USD 28,462
|
|
|
2021-06-09 |
2021-06-07 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
1,400
-9.3%
30.35
USD 42,496
|
1,400
-9.3%
|
30.35
|
USD 42,496
|
|
|
2021-05-27 |
2021-05-25 |
PS
Planned sale
|
Piper Brian
Chief Financial Officer
Officer
|
399
-100.0%
36.09
USD 14,401
|
399
-100.0%
|
36.09
|
USD 14,401
|
|
|
2021-05-27 |
2021-05-25 |
PS
Planned sale
|
Piper Brian
Chief Financial Officer
Officer
|
1,736
-81.3%
35.45
USD 61,536
|
1,736
-81.3%
|
35.45
|
USD 61,536
|
|
|
2021-05-27 |
2021-05-25 |
PS
Planned sale
|
Piper Brian
Chief Financial Officer
Officer
|
3,088
-59.1%
34.11
USD 105,338
|
3,088
-59.1%
|
34.11
|
USD 105,338
|
|
|
2021-05-27 |
2021-05-25 |
PS
Planned sale
|
Piper Brian
Chief Financial Officer
Officer
|
3,110
-37.3%
33.53
USD 104,263
|
3,110
-37.3%
|
33.53
|
USD 104,263
|
|
|
2021-05-11 |
2021-05-07 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
200
-0.1%
41.85
USD 8,370
|
200
-0.1%
|
41.85
|
USD 8,370
|
|
|
2021-05-11 |
2021-05-07 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
5,836
-3.3%
41.14
USD 240,090
|
5,836
-3.3%
|
41.14
|
USD 240,090
|
|
|
2021-05-11 |
2021-05-07 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
3,964
-2.2%
40.30
USD 159,732
|
3,964
-2.2%
|
40.30
|
USD 159,732
|
|
|
2021-05-10 |
2021-05-05 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
1,109
-100.0%
41.07
USD 45,545
|
1,109
-100.0%
|
41.07
|
USD 45,545
|
|
|
2021-05-10 |
2021-05-05 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
10,476
-90.4%
40.30
USD 422,148
|
10,476
-90.4%
|
40.30
|
USD 422,148
|
|
|
2021-05-10 |
2021-05-05 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
3,415
-22.8%
39.36
USD 134,399
|
3,415
-22.8%
|
39.36
|
USD 134,399
|
|
|
2021-04-30 |
2021-04-29 |
PS
Planned sale
|
Pierce Christopher
EVP and Chief of Business Oper
Officer
|
3,295
-46.8%
40.29
USD 132,765
|
3,295
-46.8%
|
40.29
|
USD 132,765
|
|
|
2021-04-30 |
2021-04-29 |
PS
Planned sale
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Officer
|
3,223
-87.9%
40.29
USD 129,853
|
3,223
-87.9%
|
40.29
|
USD 129,853
|
|
|
2021-04-29 |
2021-04-27 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
1,711
-100.0%
36.11
USD 61,791
|
1,711
-100.0%
|
36.11
|
USD 61,791
|
|
|
2021-04-29 |
2021-04-27 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
15,601
-90.1%
35.68
USD 556,580
|
15,601
-90.1%
|
35.68
|
USD 556,580
|
|
|
2021-04-29 |
2021-04-27 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
7,688
-30.8%
34.66
USD 266,478
|
7,688
-30.8%
|
34.66
|
USD 266,478
|
|
|
2021-04-21 |
2021-04-19 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
4,000
-100.0%
31.27
USD 125,077
|
4,000
-100.0%
|
31.27
|
USD 125,077
|
|
|
2021-04-21 |
2021-04-19 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
21,000
-84.0%
30.82
USD 647,273
|
21,000
-84.0%
|
30.82
|
USD 647,273
|
|
|
2021-04-15 |
2021-04-08 |
PS
Planned sale
|
Pierce Christopher
EVP and Chief of Business Oper
Officer
|
200
-5.1%
40.00
USD 8,000
|
200
-5.1%
|
40.00
|
USD 8,000
|
|
|
2021-04-15 |
2021-04-08 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
1,669
-1.0%
39.57
USD 66,040
|
1,669
-1.0%
|
39.57
|
USD 66,040
|
|
|
2021-04-15 |
2021-04-08 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
669
-0.4%
38.97
USD 26,073
|
669
-0.4%
|
38.97
|
USD 26,073
|
|
|
2021-04-15 |
2021-04-08 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
875
-0.5%
37.72
USD 33,003
|
875
-0.5%
|
37.72
|
USD 33,003
|
|
|
2021-04-15 |
2021-04-08 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
1,417
-0.8%
36.97
USD 52,387
|
1,417
-0.8%
|
36.97
|
USD 52,387
|
|
|
2021-04-09 |
2021-04-07 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
200
-0.1%
40.30
USD 8,060
|
200
-0.1%
|
40.30
|
USD 8,060
|
|
|
2021-04-09 |
2021-04-07 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
6,881
-3.8%
39.63
USD 272,679
|
6,881
-3.8%
|
39.63
|
USD 272,679
|
|
|
2021-04-09 |
2021-04-07 |
PS
Planned sale
|
Scherle Peggy
Chief Scientific Officer
Officer
|
8,289
-4.4%
39.02
USD 323,405
|
8,289
-4.4%
|
39.02
|
USD 323,405
|
|
|
2021-04-09 |
2021-04-07 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
7,083
-100.0%
39.69
USD 281,116
|
7,083
-100.0%
|
39.69
|
USD 281,116
|
|
|
2021-04-09 |
2021-04-07 |
PS
Planned sale
|
Mauro David J
Chief Medical Officer
Officer
|
8,300
-54.0%
39.03
USD 323,908
|
8,300
-54.0%
|
39.03
|
USD 323,908
|
|
|
2020-09-29 |
2020-09-29 |
B
Purchase
|
Combs Andrew
EVP, Head of Chemistry
Officer
|
1,000
+0.4%
19.00
USD 19,000
|
1,000
+0.4%
|
19.00
|
USD 19,000
|
|
|
2020-09-29 |
2020-09-29 |
B
Purchase
|
Morosini Deborah
EVP, Chief of Clinical Affairs
Officer
|
444
+inf%
19.00
USD 8,436
|
444
+inf%
|
19.00
|
USD 8,436
|
|
|
2020-09-29 |
2020-09-29 |
B
Purchase
|
Dier Mardi
Non-Executive Director
|
10,000
+inf%
19.00
USD 190,000
|
10,000
+inf%
|
19.00
|
USD 190,000
|
|
|
2020-09-29 |
2020-09-29 |
B
Purchase
|
Pierce Christopher
EVP and Chief of Business Oper
Officer
|
3,750
+inf%
19.00
USD 71,250
|
3,750
+inf%
|
19.00
|
USD 71,250
|
|
|
2020-09-29 |
2020-09-25 |
B
Purchase
|
ORBIMED ADVISORS LLC
Non-Executive Director
Large shareholder
|
710,500
+343.4%
19.00
USD 13,499,500
|
710,500
+343.4%
|
19.00
|
USD 13,499,500
|
|
|
2020-09-29 |
2020-09-25 |
B
Purchase
|
ORBIMED ADVISORS LLC
Non-Executive Director
Large shareholder
|
526,300
+inf%
19.00
USD 9,999,700
|
526,300
+inf%
|
19.00
|
USD 9,999,700
|
|
